Nucleoporin 107 is a Prognostic Biomarker in Hepatocellular Carcinoma Associated with Immune Infiltration

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Mar 23

PMID 36952458

Authors

Ju-Sen Nong

Xin Zhou

Jun-Qi Liu

Jian-Zhu Luo

Jia-Mi Huang

Hai-Xiang Xie

Ke-Jian Yang

Jing Wang

Xin-Ping Ye

Tao Peng

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the diagnostic value and clinical significance of nucleoporin 107 (NUP107) in hepatocellular carcinoma (HCC), and explore the possible mechanisms.

Methods: The transcriptomic and clinical data of HCC patients were retrieved from The Cancer Genome Atlas (TCGA) and GEO databases. Tissue specimens were collected from HCC patients in the Guangxi area. According to the expression levels and prognostic characteristics of NUP107, ROC curves and nomogram models were constructed using the R package.

Results: NUP107 was highly expressed in 26 human cancers including HCC, and was associated with advanced HCC staging and worse prognosis. NUP107 showed satisfactory ability to predict the prognosis of HCC patients (AUC >0.8). Results of gene set enrichment analysis (GSEA) further showed that NUP107 was mainly associated with cell cycle-related pathways such as the cell cycle, DNA replication, G2M checkpoint, E2F target, and mitotic spindle. In addition, NUP107 was also associated with immune infiltration in HCC and showed significant positive correlation with immune checkpoints (PD-L1 and TIM-3).

Citing Articles

Nuclear envelope and chromatin choreography direct cellular differentiation.

Nair A, Khanna J, Kler J, Ragesh R, Sengupta K Nucleus. 2025; 16(1):2449520.

PMID: 39943681 PMC: 11834525. DOI: 10.1080/19491034.2024.2449520.

Advances in the understanding of nuclear pore complexes in human diseases.

Li Y, Zhu J, Zhai F, Kong L, Li H, Jin X J Cancer Res Clin Oncol. 2024; 150(7):374.

PMID: 39080077 PMC: 11289042. DOI: 10.1007/s00432-024-05881-5.

Prognostic significance of LRPPRC and its association with immune infiltration in liver hepatocellular carcinoma.

Zhang Y, Feng B, Liang Y, Tang Q, Zhang S, Zhang Z Am J Clin Exp Immunol. 2024; 13(3):105-116.

PMID: 39022790 PMC: 11249856. DOI: 10.62347/XTLJ1335.

Mutations in the NUP93, NUP107 and NUP160 genes cause steroid-resistant nephrotic syndrome in Chinese children.

Han Y, Sha H, Yang Y, Yu Z, Zhou L, Wang Y Ital J Pediatr. 2024; 50(1):81.

PMID: 38650033 PMC: 11036785. DOI: 10.1186/s13052-024-01656-3.

Unveiling the landscape of cytokine research in glioma immunotherapy: a scientometrics analysis.

Zhang H, Chen Y, Jiang X, Gu Q, Yao J, Wang X Front Pharmacol. 2024; 14:1333124.

PMID: 38259287 PMC: 10800575. DOI: 10.3389/fphar.2023.1333124.

References

Zuccolo M, Alves A, Galy V, Bolhy S, Formstecher E, Racine V . The human Nup107-160 nuclear pore subcomplex contributes to proper kinetochore functions. EMBO J. 2007; 26(7):1853-64. PMC: 1847668. DOI: 10.1038/sj.emboj.7601642. View

Nong J, Zhou X, Liu J, Luo J, Huang J, Xie H . Nucleoporin 107 is a prognostic biomarker in hepatocellular carcinoma associated with immune infiltration. Cancer Med. 2023; 12(9):10990-11009. PMC: 10225238. DOI: 10.1002/cam4.5807. View

Shimozono N, Jinnin M, Masuzawa M, Masuzawa M, Wang Z, Hirano A . NUP160-SLC43A3 is a novel recurrent fusion oncogene in angiosarcoma. Cancer Res. 2015; 75(21):4458-65. DOI: 10.1158/0008-5472.CAN-15-0418. View

Belgareh N, Rabut G, Bai S, van Overbeek M, Beaudouin J, Daigle N . An evolutionarily conserved NPC subcomplex, which redistributes in part to kinetochores in mammalian cells. J Cell Biol. 2001; 154(6):1147-60. PMC: 2150808. DOI: 10.1083/jcb.200101081. View

Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589-604. PMC: 6813818. DOI: 10.1038/s41575-019-0186-y. View

Llovet J, Castet F, Heikenwalder M, Maini M, Mazzaferro V, Pinato D . Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2021; 19(3):151-172. DOI: 10.1038/s41571-021-00573-2. View

Wei Y, Yang C, Wei Z, Liao X, He Y, Zhou X . High-Mobility Group AT-Hook 1 Served as a Prognosis Biomarker and Associated with Immune Infiltrate in Hepatocellular Carcinoma. Int J Gen Med. 2022; 15:609-621. PMC: 8765458. DOI: 10.2147/IJGM.S344858. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Waidmann O . Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther. 2018; 18(8):905-910. DOI: 10.1080/14712598.2018.1499722. View

10.

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

11.

Alanee S, Delfino K, Wilber A, Robinson K, Brard L, Semaan A . Single nucleotide variant in Nucleoporin 107 may be predictive of sensitivity to chemotherapy in patients with ovarian cancer. Pharmacogenet Genomics. 2017; 27(7):264-269. PMC: 6298606. DOI: 10.1097/FPC.0000000000000288. View

12.

Lee J, Lee J, Lim Y, Yeon J, Song T, Yu S . Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother. 2018; 68(1):23-32. PMC: 6326973. DOI: 10.1007/s00262-018-2247-4. View

13.

Wang M, Chang M, Li C, Chen Q, Hou Z, Xing B . Tumor-Microenvironment-Activated Reactive Oxygen Species Amplifier for Enzymatic Cascade Cancer Starvation/Chemodynamic /Immunotherapy. Adv Mater. 2021; 34(4):e2106010. DOI: 10.1002/adma.202106010. View

14.

Kim S, Kang H, Choi H, Park S . Reduction of Nup107 attenuates the growth factor signaling in the senescent cells. Biochem Biophys Res Commun. 2010; 401(1):131-6. DOI: 10.1016/j.bbrc.2010.09.025. View

15.

Zheng X, Yang S, Han Y, Zhao X, Zhao L, Tian T . Loss of zygotic NUP107 protein causes missing of pharyngeal skeleton and other tissue defects with impaired nuclear pore function in zebrafish embryos. J Biol Chem. 2012; 287(45):38254-64. PMC: 3488094. DOI: 10.1074/jbc.M112.408997. View

16.

Wei Z, Zhou X, Lan C, Huang H, Liao X, Mo S . Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma. BMC Gastroenterol. 2022; 22(1):77. PMC: 8864914. DOI: 10.1186/s12876-022-02152-w. View

17.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

18.

Woodruff M . Cellular heterogeneity in tumours. Br J Cancer. 1983; 47(5):589-94. PMC: 2011371. DOI: 10.1038/bjc.1983.96. View

19.

Griffith J, Sokol C, Luster A . Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014; 32:659-702. DOI: 10.1146/annurev-immunol-032713-120145. View

20.

Sperandio R, Carmagnani Pestana R, Miyamura B, Kaseb A . Hepatocellular Carcinoma Immunotherapy. Annu Rev Med. 2021; 73:267-278. DOI: 10.1146/annurev-med-042220-021121. View